© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
Incorporating Genomics into Lymphoma Classification Can Improve Care
November 21, 2020
The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.
FDA Postpones Review of BLA for Liso-Cel in R/R Large B-Cell Lymphoma
November 16, 2020
The FDA will not complete its review of the Biologics License Application for lisocabtagene maraleucel for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 prior lines of therapy by the Prescription Drug User Fee Act action date of November 16, 2020.
In Low-Grade Follicular Lymphoma, Expert Weighs Frontline Options
November 04, 2020
A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.
Collaboration Between Oncologists and Pathologists Benefit Patients
October 28, 2020
Andre Goy, MD, MS, discusses the benefits of working with a pathologist to develop a better understanding of molecular oncology and optimal treatment decisions for patients with lymphomas.
Enhanced Radioisotope Yields Unique Therapeutic CLR 131 in Lymphoplasmacytic Lymphoma
October 25, 2020
The CLOVER-1 study is testing CLR 131 in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
FDA Approves Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
October 15, 2020
The FDA granted approval to the immune checkpoint inhibitor pembrolizumab as treatment of patients with relapsed or refractory classic Hodgkin lymphoma.
Targeted Therapies Offer New Treatment Options for R/R MZL Across Subtypes
October 10, 2020
Marginal zone lymphomas are a heterogenous group of B-cell non-Hodgkin lymphomas based on their etiology and clinical presentation, and as such, treatment for these diseases vary by subtype, according to Stephen Douglas Smith, MD.
Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk
October 10, 2020
When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.
Targeted Treatments, Cell Therapies Are Explored in Double-Hit Lymphoma
October 10, 2020
The most recent updated World Health Organization classification of lymphoid neoplasms included a new category of mature B-cell neoplasms, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations.
Pro Talks Treatment for Peripheral T-Cell Lymphoma
October 07, 2020
During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.